Cargando…

Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit

Two series of novel sorafenib analogs containing a sulfonylurea unit were synthesized and their chemical structures were confirmed by (1)H-NMR, (1)(3)C-NMR, MS spectrum and elemental analysis. The synthesized compounds were evaluated for the cytotoxicity against A549, Hela, MCF-7, and PC-3 cancer ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chunjiang, Wang, Min, Tang, Qidong, Luo, Rong, Chen, Le, Zheng, Pengwu, Zhu, Wufu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332012/
https://www.ncbi.nlm.nih.gov/pubmed/26512636
http://dx.doi.org/10.3390/molecules201019361
_version_ 1783387249942986752
author Wu, Chunjiang
Wang, Min
Tang, Qidong
Luo, Rong
Chen, Le
Zheng, Pengwu
Zhu, Wufu
author_facet Wu, Chunjiang
Wang, Min
Tang, Qidong
Luo, Rong
Chen, Le
Zheng, Pengwu
Zhu, Wufu
author_sort Wu, Chunjiang
collection PubMed
description Two series of novel sorafenib analogs containing a sulfonylurea unit were synthesized and their chemical structures were confirmed by (1)H-NMR, (1)(3)C-NMR, MS spectrum and elemental analysis. The synthesized compounds were evaluated for the cytotoxicity against A549, Hela, MCF-7, and PC-3 cancer cell lines. Some of the compounds showed moderate cytotoxic activity, especially compounds 1-(2,4-difluorophenylsulfonyl)-3-(4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea (6c) and 1-(4-bromophenylsulfonyl)-3-(4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea (6f) with the IC(50) values against four cancer cell lines ranging from 16.54 ± 1.22 to 63.92 ± 1.81 μM, respectively. Inhibitory rates against vascular endothelial growth factor receptor-2 (VEGFR2/KDR) kinase at 10 μM of target compounds were further carried out in this paper in order to investigate the target of these compounds. Structure-activity relationships (SARs) and docking studies indicated that the sulfonylurea unit was important to these kinds of compounds. None of the substitutions in the phenoxy group and small halogen atoms such as 2,4-difluoro substitution of the aryl group contributed to the activity. The results suggested that sulfonylurea sorafenib analogs are worthy of further study.
format Online
Article
Text
id pubmed-6332012
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63320122019-01-24 Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit Wu, Chunjiang Wang, Min Tang, Qidong Luo, Rong Chen, Le Zheng, Pengwu Zhu, Wufu Molecules Article Two series of novel sorafenib analogs containing a sulfonylurea unit were synthesized and their chemical structures were confirmed by (1)H-NMR, (1)(3)C-NMR, MS spectrum and elemental analysis. The synthesized compounds were evaluated for the cytotoxicity against A549, Hela, MCF-7, and PC-3 cancer cell lines. Some of the compounds showed moderate cytotoxic activity, especially compounds 1-(2,4-difluorophenylsulfonyl)-3-(4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea (6c) and 1-(4-bromophenylsulfonyl)-3-(4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea (6f) with the IC(50) values against four cancer cell lines ranging from 16.54 ± 1.22 to 63.92 ± 1.81 μM, respectively. Inhibitory rates against vascular endothelial growth factor receptor-2 (VEGFR2/KDR) kinase at 10 μM of target compounds were further carried out in this paper in order to investigate the target of these compounds. Structure-activity relationships (SARs) and docking studies indicated that the sulfonylurea unit was important to these kinds of compounds. None of the substitutions in the phenoxy group and small halogen atoms such as 2,4-difluoro substitution of the aryl group contributed to the activity. The results suggested that sulfonylurea sorafenib analogs are worthy of further study. MDPI 2015-10-23 /pmc/articles/PMC6332012/ /pubmed/26512636 http://dx.doi.org/10.3390/molecules201019361 Text en © 2015 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wu, Chunjiang
Wang, Min
Tang, Qidong
Luo, Rong
Chen, Le
Zheng, Pengwu
Zhu, Wufu
Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit
title Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit
title_full Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit
title_fullStr Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit
title_full_unstemmed Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit
title_short Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit
title_sort design, synthesis, activity and docking study of sorafenib analogs bearing sulfonylurea unit
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332012/
https://www.ncbi.nlm.nih.gov/pubmed/26512636
http://dx.doi.org/10.3390/molecules201019361
work_keys_str_mv AT wuchunjiang designsynthesisactivityanddockingstudyofsorafenibanalogsbearingsulfonylureaunit
AT wangmin designsynthesisactivityanddockingstudyofsorafenibanalogsbearingsulfonylureaunit
AT tangqidong designsynthesisactivityanddockingstudyofsorafenibanalogsbearingsulfonylureaunit
AT luorong designsynthesisactivityanddockingstudyofsorafenibanalogsbearingsulfonylureaunit
AT chenle designsynthesisactivityanddockingstudyofsorafenibanalogsbearingsulfonylureaunit
AT zhengpengwu designsynthesisactivityanddockingstudyofsorafenibanalogsbearingsulfonylureaunit
AT zhuwufu designsynthesisactivityanddockingstudyofsorafenibanalogsbearingsulfonylureaunit